Whole genome analysis of the action of interferon-β

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 5, 2009, Pages 328-357

  Kauffman, M A ^a   Yankilevich, P ^a   Barrero, P ^b   Bello, R ^a   Marangunich, L ^a   Vidal, A ^a   Criscuolo, M ^a   Diez, R A ^a   Sterin Prync, A ^a  

^a Bio Sidus   (Argentina)

^b HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

Author keywords

Genomics; Interferon ; Microarray; Multiple sclerosis; Treatment

Indexed keywords

ADENOSINE A2B RECEPTOR; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BETA DEFENSIN 1; BETA1A INTERFERON; CALGRANULIN A; CALVASCULIN; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CYTIDINE DEAMINASE; FRUCTOSE 1,6 BISPHOSPHATE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 7; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 3; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 2; NEUROGRANIN; PROTEIN FOS; PURINERGIC P2Y6 RECEPTOR; RETINOL BINDING PROTEIN; RETINOL BINDING PROTEIN 7; STAT1 PROTEIN; STAT2 PROTEIN; STEM CELL FACTOR; TRANSCOBALAMIN II; UNCLASSIFIED DRUG; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADOLESCENT; ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HUMAN; IN VITRO STUDY; LEUKOCYTE; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; UNINDEXED SEQUENCE; UPREGULATION; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; HUMAN GENOME; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME, HUMAN; HUMANS; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 67649407620     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47328     Document Type: Article

References (41)

1. Ambrosini E, Remoli ME, Giacomini E, Rosicarelli B, Serafini B, Lande R, Aloisi F, Coccia EM. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol. 2005; 64: 706-715.
2. Bandyopadhyay G, De A, Laudanski K, Li F, Lentz C, Bankey P, Miller-Graziano C. Negative signaling contributes to T cell anergy in trauma patients. Crit Care Med. 2007; 35: 794-801.
3. Beinhauer BG, McBride JM, Graf P, Pursch E, Bongers M, Rogy M, Korthauer U, de Vries JE, Aversa G, Jung T. Interleukin 10 regulates cell surface and soluble LIR-2 (CD85d) expression on dendritic cells resulting in T cell hyporesponsiveness in vitro. Eur J Immunol. 2004; 34: 74-80.
4. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354: 610-621.
5. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, Blumenschein W, Churakovsa T, Low J, Presta L, Hunter CA, Kastelein RA, Cua DJ. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest. 2006; 116: 1317-1326.
6. Comabella M, Martin R. Genomics in multiple sclerosis-Current state and future directions. J Neuroimmunol. 2007; 187: 1-8.
7. Cudrici C, Niculescu F, Jensen T, Zafranskaia E, Fosbrink M, Rus V, Shin ML, Rus H. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol. 2006; 176: 3173-3180.
8. Dudoit S, Gentleman RC, Quackenbush J. Open source software for the analysis of microarray data. Biotechniques. 2003; (Suppl.): 45-51.
9. Efron B, Tibshirani R. Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol. 2002; 23: 70-86.
10. Furlan R, Rovaris M, Martinelli Boneschi F, Khademi M, Bergami A, Gironi M, Deleidi M, Agosta F, Franciotta D, Scarpini E, Uccelli A, Zaffaroni M, Kurne A, Comi G, Olsson T, Filippi M, Martino G. Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol. 2005; 165: 192-200.
11. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990; 9: 811-818.
12. Howard LM, Kohm AP, Castaneda CL, Miller SD. Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease. Curr Drug Targets Inflamm Allergy. 2005; 4: 205-216.
13. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957; 147: 258-267.
14. Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, Jozefowicz R, Cuetter A, Husain F, Smith WA, Ekes R, et al. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study. Arch Neurol. 1987; 44: 589-595.
15. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, Hofbauer M, Farina C, Derfuss T, Hartle C, Newcombe J, Hohlfeld R, Meinl E. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006; 129: 200-211.
16. Lee HK, Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol. 2007; 19: 48-55.
17. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2001; 2: 585-589.
18. Lopez C, Comabella M, Al-zayat H, Tintore M, Montalban X. Altered maturation of circulating dendritic cells in primary progressive MS patients. J Neuroimmunol. 2006; 175: 183-191.
19. Mead RJ, Neal JW, Griffiths MR, Linington C, Botto M, Lassmann H, Morgan BP. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab Invest. 2004; 84: 21-28.
20. Penberthy WT. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab. 2007; 8: 245-266.
21. Perrella O, Sbreglia C, Perrella M, Spetrini G, Gorga F, Pezzella M, Perrella A, Atripaldi L, Carrieri P. Interleukin-10 and tumor necrosis factor-α model of immunomodulation in multiple sclerosis. Neurol Res. 2006; 28: 193-195.
22. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, Gupta R, Lee LY, Kidd BA, Robinson WH, Sobel RA, Selley ML, Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005; 310: 850-855.
23. 1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998; 352: 1498-1504.
24. Rani MR, Ransohoff RM. Alternative and accessory pathways in the regulation of IFN-β-mediated gene expression. J Interferon Cytokine Res. 2005; 25: 788-798.
25. 1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 2008; 28: 317-331.
26. Rus H, Cudrici C, Niculescu F. C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection. Ann Med. 2005; 37: 97-104.
27. Sakurai K, Zou JP, Tschetter JR, Ward JM, Shearer GM. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002; 129: 186-196.
28. Satoh J, Nanri Y, Tabunoki H, Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNβ-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNβ-related adverse effects in multiple sclerosis. BMC Neurol. 2006; 6: 18.
29. Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous Tcell activation: relevance for the immune-modulatory effect in multiple sclerosis. J Neuroimmunol. 2004; 155: 172-182.
30. 1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993; 43: 655-661.
31. 1a pharmaceutical preparations produce a similar transcriptional response determined using whole genome microarray analysis. Int J Clin Pharmacol Ther. 2008; 46: 64-71.
32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005; 102: 15545-15550.
33. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol. 2006; 8: 907-922.
34. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003; 13: 2129-2141.
35. Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol. 2006; 176: 7768-7774.
36. van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, Verweij CL. Asubtype of multiple sclerosis defined by an activated immune defense program. Genes Immun. 2006; 7: 522-531.
37. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C. The Pregnancy In Multiple Sclerosis G: Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004; 127: 1353-1360.
38. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D, Baier M, Feichter J, Ramanathan M. Genomic effects of IFN-β in multiple sclerosis patients. J Immunol. 2003; 171: 2694-2702.
39. Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics. 2004; 20: 3705-3706.
40. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander ES, Kellis M. Systematic discovery of regulatory motifs in human promoters and 3'UTRs by comparison of several mammals. Nature. 2005; 434: 338-345.
41. Zhu WH, Lu CZ, Huang YM, Link H, Xiao BG. Aputative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells. Mult Scaler. 2007; 13: 33-40.